PDF herunterladen
CC BY-NC-ND 4.0 · Ibnosina Journal of Medicine and Biomedical Sciences 2022; 14(03): 086-093
DOI: 10.1055/s-0042-1759739
Review Article

Effect of COVID-19 on Serum Activity of Liver Enzymes: Is This Associated with Severity and Mortality Rate?

Seyed Ehsan Alavian
1   Middle East Liver Disease (MELD) Virology Laboratory, MELD Center, Tehran, Iran
,
Mohammad Mofidi
2   Department of Laboratory Science, Faculty of Paramedical, Golestan University of Medical Science, Gorgan, Iran
,
Fahimeh Shahabipour
3   Orthopedic Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
4   Skin Research Center, Shahid Beheshti of Medical Science, Tehran, Iran
› Institutsangaben Funding Statement This project received no specific funding.
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Introduction Coronavirus disease 2019 (COVID-19) is a viral infection caused by a novel coronavirus known as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease raises an enormous public health challenge for the international community. Liver enzymes have been reported to be frequently elevated in hospitalized patients with severe COVID-19 disease.

Materials and Methods This article is a narrative review of abnormal liver tests and liver injury as a manifestation of progression to severe pneumonia. We collected data from the PubMed database (National Library of Medicine, Bethesda, Maryland, United States). We used the search term “abnormal liver test” and relevant records were measured. The review article was organized thematically.

Results This narrative review aims to summarize the available clinical data on abnormal liver enzymes in coronavirus infection and its association with the risk of mortality, severer pneumonia, and systemic inflammation. Some clinical studies refer to abnormal liver tests and liver injury as a manifestation of progression to severe pneumonia. Recent research verified the relationship between hepatic liver enzyme activities and liver damage in patients with COVID-19, which suggested that it might reflect the infection severity and the mortality risk. Thus, this review investigated the correlation between liver serum enzymes level and the severity of COVID-19 patients, by reviewing investigating the relationship between the illness severity in COVID-19 patients with abnormal liver tests, liver pathology, and markers of inflammation.

Conclusion In the current pandemic of SARS-CoV-2, abnormalities of liver enzyme tests were commonly observed in patients with COVID-19. However, because of multiorgan damages that observed in COVID-19 patients, various issues should be considered such as the pathology and pathophysiology of the liver tissue, especially on the activation process of the immune response and cytokine storm to prevent the severity of the disease.

Keywords

COVID-19 - liver enzyme - coronavirus - liver injury - mortality

Authors' Contributions

All authors contributed to the review on effect of COVID-19 on serum activity of liver enzymes: Is this associated with severity and mortality rate? They have all assisted in writing, revision, and approval of its final version.




Publikationsverlauf

Artikel online veröffentlicht:
21. Dezember 2022

© 2022. The Libyan Authority of Scientific Research and Technology and the Libyan Biotechnology Research Center. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Liao FL, Peng DH, Chen W. et al. Evaluation of serum hepatic enzyme activities in different COVID-19 phenotypes. J Med Virol 2021; 93 (04) 2365-2373
    CrossrefPubMedSuche in Google Scholar
  • 2 Wu H, Zhu H, Yuan C. et al. Clinical and immune features of hospitalized pediatric patients with coronavirus disease 2019 (COVID-19) in Wuhan, China. JAMA Netw Open 2020; 3 (06) e2010895
    CrossrefPubMedSuche in Google Scholar
  • 3 Unudurthi SD, Luthra P, Bose RJC, McCarthy JR, Kontaridis MI. Cardiac inflammation in COVID-19: Lessons from heart failure. Life Sci 2020; Nov 1; 260: 118482
    CrossrefPubMedSuche in Google Scholar
  • 4 He L, Mäe MA, Sun Y. et al. Pericyte-specific vascular expression of SARS-CoV-2 receptor ACE2–implications for microvascular inflammation, and coagulopathy in COVID-19 patients. BioRxiv 2020;
    CrossrefSuche in Google Scholar
  • 5 Menter T, Haslbauer JD, Nienhold R. et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. Histopathology 2020; 77 (02) 198-209
    CrossrefPubMedSuche in Google Scholar
  • 6 Zhang Y, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single centre in Wuhan city, China. Liver Int 2020; 40 (09) 2095-2103
    CrossrefPubMedSuche in Google Scholar
  • 7 Lei F, Liu YM, Zhou F. et al. Longitudinal association between markers of liver injury and mortality in COVID-19 in China. Hepatology 2020; 72 (02) 389-398
    CrossrefPubMedSuche in Google Scholar
  • 8 Chai X, Hu L, Zhang Y. et al. Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection. bioRxiv 2020
    PubMedSuche in Google Scholar
  • 9 Sun Y, Dong Y, Wang L. et al. Characteristics and prognostic factors of disease severity in patients with COVID-19: the Beijing experience. J Autoimmun 2020; 112: 102473
    CrossrefPubMedSuche in Google Scholar
  • 10 Gori A, Dondossola D, Antonelli B. et al. Coronavirus disease 2019 and transplantation: a view from the inside. Am J Transplant 2020; 20 (07) 1939-1940
    CrossrefPubMedSuche in Google Scholar
  • 11 Cheong J, Bartell N, Peeraphatdit T, Mosli M, Al-Judaibi B. Gastrointestinal and liver manifestations of COVID-19. Saudi J Gastroenterol 2020; 26 (05) 226-232
    CrossrefPubMedSuche in Google Scholar
  • 12 Mishra K, Naffouj S, Gorgis S. et al. Liver injury as a surrogate for inflammation and predictor of outcomes in COVID-19. Hepatol Commun 2020; 5 (01) 24-32
    CrossrefPubMedSuche in Google Scholar
  • 13 Eastin C, Eastin T. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China: Dong Y, Mo X, Hu Y, et al. Pediatrics. 2020. J Emerg Med 2020; 58: 712-713
    CrossrefSuche in Google Scholar
  • 14 Ramachandran P, Perisetti A, Gajendran M, Chakraborti A, Narh JT, Goyal H. Increased serum aminotransferase activity and clinical outcomes in coronavirus disease 2019. J Clin Exp Hepatol 2020; 10 (06) 533-539
    CrossrefPubMedSuche in Google Scholar
  • 15 Li L, Li S, Xu M. et al. Risk factors related to hepatic injury in patients with coronavirus disease 2019. MedRxiv 2020
    PubMedSuche in Google Scholar
  • 16 Cai Q, Chen J. Reply to: “Clinical characteristics of COVID-19 patients with abnormal liver tests”. J Hepatol 2020; 73 (03) 713-714
    CrossrefPubMedSuche in Google Scholar
  • 17 Zhang B, Zhou X, Qiu Y. et al. Clinical characteristics of 82 cases of death from COVID-19. PLoS One 2020; 15 (07) e0235458
    CrossrefPubMedSuche in Google Scholar
  • 18 Huang Y, Zhou H, Yang R, Xu Y, Feng X, Gong P. Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan, China. MedRxiv 2020
    PubMedSuche in Google Scholar
  • 19 Gholizadeh P, Safari R, Marofi P. et al. Alteration of liver biomarkers in patients with SARS-CoV-2 (COVID-19). J Inflamm Res 2020; 13: 285-292
    CrossrefPubMedSuche in Google Scholar
  • 20 Hwaiz R, Merza M, Hamad B, HamaSalih S, Mohammed M, Hama H. Evaluation of hepatic enzymes activities in COVID-19 patients. Int Immunopharmacol 2021; 97: 107701
    CrossrefPubMedSuche in Google Scholar
  • 21 Li B, Yang J, Zhao F. et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020; 109 (05) 531-538
    CrossrefPubMedSuche in Google Scholar
  • 22 Mehta N, Kalra A, Nowacki AS. et al. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020; 5 (09) 1020-1026
    CrossrefPubMedSuche in Google Scholar
  • 23 Chakraborty C, Sharma AR, Bhattacharya M, Sharma G, Lee SS, Agoramoorthy G. COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients. J Med Virol 2020; 92 (11) 2260-2262
    CrossrefPubMedSuche in Google Scholar
  • 24 Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. et al. HLH across speciality collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395 (10229): 1033-1034
    CrossrefPubMedSuche in Google Scholar
  • 25 Effenberger M, Grander C, Grabherr F. et al. Systemic inflammation as fuel for acute liver injury in COVID-19. Dig Liver Dis 2021; 53 (02) 158-165
    CrossrefPubMedSuche in Google Scholar
  • 26 Wang Q, Zhao H, Liu L-G. et al. Pattern of liver injury in adult patients with COVID-19: a retrospective analysis of 105 patients. Mil Med Res 2020; 7 (01) 28
    PubMedSuche in Google Scholar
  • 27 Vishwajeet V, Purohit A, Kumar D. et al. Evaluation of liver histopathological findings of coronavirus disease 2019 by minimally invasive autopsies. J Clin Exp Hepatol 2022; 12 (02) 390-397
    CrossrefPubMedSuche in Google Scholar
  • 28 Li N, Liu T, Chen H. et al. Management strategies for the burn ward during COVID-19 pandemic. Burns 2020; 46 (04) 756-761
    CrossrefPubMedSuche in Google Scholar
  • 29 Ding ZY, Li GX, Chen L. et al; Tongji Multidisciplinary Team for Treating COVID-19 (TTTC). Association of liver abnormalities with in-hospital mortality in patients with COVID-19. J Hepatol 2021; 74 (06) 1295-1302
    CrossrefPubMedSuche in Google Scholar
  • 30 Zhao CL, Rapkiewicz A, Maghsoodi-Deerwester M. et al. Pathological findings in the postmortem liver of patients with coronavirus disease 2019 (COVID-19). Hum Pathol 2021; 109: 59-68
    CrossrefPubMedSuche in Google Scholar
  • 31 Schmit G, Lelotte J, Vanhaebost J, Horsmans Y, Van Bockstal M, Baldin P. The liver in COVID-19-related death: protagonist or innocent bystander?. Pathobiology 2021; 88 (01) 88-94
    CrossrefPubMedSuche in Google Scholar
  • 32 Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis 2020; 71 (15) 769-777
    CrossrefPubMedSuche in Google Scholar
  • 33 Fan Z, Chen L, Li J. et al. Clinical features of COVID-19-related liver functional abnormality. Clin Gastroenterol Hepatol 2020; 18 (07) 1561-1566
    CrossrefPubMedSuche in Google Scholar
  • 34 Qian GQ, Yang N-B, Ding F. et al. Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: a retrospective, multi-centre case series. QJM 2020; 113 (07) 474-481
    CrossrefPubMedSuche in Google Scholar
  • 35 Yang X, Yu Y, Xu J. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 8 (05) 475-481
    CrossrefPubMedSuche in Google Scholar
  • 36 Feng G, Zheng KI, Yan QQ. et al. COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies. J. Clin. Transl. Hepatol 2020; 8: 18-24
    CrossrefPubMedSuche in Google Scholar